CXCR4 is a chemokine receptor that governs how cells move. It is also one of the routes a tumour can use to spread, which is why it has been pursued as an oncology target for two decades. Balixafortide is the peptide antagonist that took that target furthest into clinical development.
The target
CXCR4 is a G-protein-coupled receptor whose endogenous ligand is CXCL12 (stromal-cell-derived factor-1). It regulates the homing of haematopoietic and immune cells. It is over-expressed in many solid and haematological tumours and has been implicated in metastasis, in the retention of malignant cells in protective niches, and in resistance to therapy. Because CXCR4 is a well-characterised, druggable receptor, it is a long-standing research target rather than a novel hypothesis.
Balixafortide
Balixafortide (POL6326) is a synthetic cyclic peptide and a selective CXCR4 antagonist, developed by Polyphor AG (later Spexis AG). A Phase 1/2 study combining it with eribulin in HER2-negative metastatic breast cancer, published in Lancet Oncology in 2018, reported activity that supported a pivotal trial. The Phase 3 FORTRESS study (NCT03786094) compared balixafortide plus eribulin with eribulin alone. In its June 2021 update, the combination had not improved objective response rate, missing the trial's coprimary endpoint, and the development line in that indication was stopped.
The wider class
CXCR4 antagonism is a broader field than its one peptide drug. Most agents in clinical development against the receptor are small molecules. Peptide reagents also appear on the diagnostic side; gallium-68 pentixafor, for example, is a peptide-based imaging agent used in research settings. The peptide class has therefore produced a well-validated tracer and one advanced therapeutic candidate, rather than a marketed medicine.
The UK position
Balixafortide holds no marketing authorisation in the UK or the EU; it is an investigational compound. Under the Medicines Act 1968 and the Human Medicines Regulations 2012, material supplied for research use is not a licensed medicine and carries no assurance of identity, purity, sterility or endotoxin content. Research-use-only products are not for human use. This article describes the research record; it is not clinical guidance and contains no dosing information.
Evidence grade
Evidence grade for balixafortide: Limited. A Phase 1/2 signal was not reproduced as a response benefit in the randomised Phase 3; the compound's clinical future rests on other indications or combinations, and there is no human data justifying any therapeutic claim. Mechanism evidence for CXCR4 as a target is stronger than the drug-level evidence, and the two should not be conflated.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.